A Closer Look at 25 Analyst Recommendations For Edwards Lifesciences
Portfolio Pulse from Benzinga Insights
Analysts have varied opinions on Edwards Lifesciences (NYSE:EW), with recent ratings showing a mix of bullish and indifferent sentiments. The average 12-month price target has decreased by 14.84% to $81.0. Analysts have mostly lowered their price targets, reflecting changing market conditions and company performance. Despite this, Edwards Lifesciences shows strong financial metrics, including a high net margin and low debt-to-equity ratio.
October 01, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Edwards Lifesciences (NYSE:EW) has received mixed analyst ratings, with a decrease in the average 12-month price target to $81.0. Analysts have mostly lowered their price targets, indicating cautious sentiment. Despite this, the company maintains strong financial metrics, including a high net margin and low debt-to-equity ratio.
The majority of analysts have lowered their price targets for Edwards Lifesciences, indicating a cautious outlook. The average price target has decreased significantly, suggesting potential short-term downward pressure on the stock price. However, the company's strong financial metrics, such as high net margin and low debt-to-equity ratio, provide a positive long-term outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100